title: Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
abstract: Acute Graft-versus-Host-Disease (aGvHD) is one of the major complications following allogeneic hematopoietic stem cell transplantation (HSCT). Although rather helpful, the use of conventional immunosuppressive drugs leads to general immunosuppression and is toxic. The effects of CD4(+) T-cells, in respect to the development of aGvHD, can be altered by administration of antihuman CD4 monoclonal antibodies, here MAX.16H5 IgG1 . This approach must be tested for possible interference with the Graft-versus-Leukemia-Effect (GvL). Thus, in vitro experiments were conducted, exposing P815 leukemic cells to bone marrow and splenocytes from cd4(-/-) -C57Bl/6 mice transgenic for human CD4 and HLA-DR3 (triple transgenic mice, [TTG]) as well as previously irradiated splenocytes from Balb/c(wt) mice. Using flow cytometry, the vitality of the various malignant and graft cells was analyzed over the course of 4 days. The survival rate of P815 cells did not change significantly when exposed to MAX.16H5 IgG1 , neither did the viability of the graft cells. This provides evidence that MAX.16H5 IgG1 does not impair the GvL effect in vitro. Additionally, P815-Balb/c(wt) leukemic mice were transplanted with P815(GFP) cells, bone marrow, and splenocytes from TTG mice with and without MAX.16H5 IgG1 . Without transplantation, P815(GFP) leukemic cells could be detected by flow cytometry in the liver, the bone marrow, and the spleen of recipients. The antibodies prevented aGvHD while leaving the GvL effect intact. These findings indicate no negative effect of MAX.16H5 IgG1 on the GvL effect in vitro and in vivo after HSCT in a murine model.
authors.affiliation: Department of Immunology, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
authors.forename: Felix
authors.initials: F
authors.lastname: Schmidt
authors.forename: Nadja
authors.initials: N
authors.lastname: Hilger
authors.forename: Christoper
authors.initials: C
authors.lastname: Oelkrug
authors.forename: Ellen
authors.initials: E
authors.lastname: Svanidze
authors.forename: Peter
authors.initials: P
authors.lastname: Ruschpler
authors.forename: Wolfram
authors.initials: W
authors.lastname: Eichler
authors.forename: Andreas
authors.initials: A
authors.lastname: Boldt
authors.forename: Frank
authors.initials: F
authors.lastname: Emmrich
authors.forename: Stephan
authors.initials: S
authors.lastname: Fricke
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D015704:CD4 Antigens / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D002470:Cell Survival; D005434:Flow Cytometry; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control; D020544:Graft vs Leukemia Effect / Q000276:immunology*; D049452:Green Fluorescent Proteins; D015803:HLA-DR3 Antigen / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D007938:Leukemia / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008099:Liver / Q000166:cytology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D013154:Spleen / Q000166:cytology / Q000473:pathology; D014184:Transplantation, Homologous
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D015803:HLA-DR3 Antigen; D049452:Green Fluorescent Proteins
keywords: Graft-Versus-Host-Disease; Graft-Versus-Leukemia-Effect; bone marrow cells; flow cytometry; hematopoietic stem cell transplantation; triple transgenic mice